image dons

I make a donation

ABOARD

Evaluating the impact of chronological strategy of catheterism on ischemic events in patients with acute coronary syndromes receiving maximal medical treatment including abciximab in case of angioplasty

Terminée

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

logo étude

objectif

Optimal time for catheterization in NSTEMI-ACS patients with impaired renal function

date de réalisation

2009

nombre de patients

350

nombre de centres participants

13 french centers

type de financement

Public (APHP) and private (Eli Lilly)

Référence

NCT00442949

Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention (The ABOARD Study)

Study Description

We propose to evaluate the optimal moment for catheterization in patients presenting with acute coronary syndromes by comparing rapid catheterization on the day of admission (within 8 hours of admission, with an average time close to 3 hours, as in the rapid strategy arm of the ISAR-COOL trial) with a slower approach where the examination is scheduled for the next working day (8 to 60 hours post admission, with an average close to 24 hours).
Patients included will present with severe unstable angina defined as a TIMI score >3. All patients must present with an indication for catheterization and they will receive the same optimal pharmacological treatment including abciximab (ReoPro®) when undergoing PCI and started just before the procedure as indicated in the label of the drug (substitution by another drug of the class, eptifibatide or tirofiban, is not possible in the catheterization laboratory according to the labels of these two other drugs).
Randomization will evaluate only time to catheterization : rapidly, as soon as possible following admission (within 8 hours of admission) versus a delayed approach (8 to 60 hours following admission). The goal of randomization is to determine the ideal time to catheterization while indications for catheterization, pharmacological treatment, and patient care remain constant. This is a pragmatic study aiming to compare 2 different strategies in the management of ACS

source clinicaltrials.gov

Publications

  • Optimal time for catheterization in NSTE-ACS patients with impaired renal function : insights from the ABOARD Study
    O Barthélémy, G Cayla, J Silvain, S A O'Connor, A Bellemain-Appaix, F Beygui, G Sideris, O Varenne, J P Collet, E Vicaut, G Montalescot, ABOARD Investigators
    Publicated in International Journal of Cardiology
  • Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study
    G Cayla, J Silvain, O Barthelemy, S 'O Connor, L Payot, A Bellemain-Appaix, F Beygui, M Aout, J-P Collet, E Vicaut, G Montalescot, ABOARD investigators
    Publicated in Heart
  • Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial
    Gilles Montalescot, Guillaume Cayla, Jean-Philippe Collet, Simon Elhadad, Farzin Beygui, Hervé Le Breton, Rémi Choussat, Florence Leclercq, Johanne Silvain, François Duclos, Mounir Aout, Jean-Luc Dubois-Randé, Olivier Barthélémy, Grégory Ducrocq, Anne Bellemain-Appaix, Laurent Payot, Philippe-Gabriel Steg, Patrick Henry, Christian Spaulding, Eric Vicaut, ABOARD Investigators
    Publicated in Journal of the American Medical Association

Autres études

+

ARAMIS

En cours


Evaluation of Anakinra versus placebo in treatment of acute myocarditis and evaluation of the contuity of the reference treatment with IEC in patients without ventricular dysfunction ventriculaire.
+

AFLOAT

En cours


To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.
+

AFLOAT

En cours


To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.